Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases.

Another stock from the same industry, Capricor Therapeutics (CAPR), has yet to report results for the quarter ended September 2024. The results are expected to be released on November 13. This ...

Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GLMX, a leading global provider of intuitive technology solutions for Repurchase ...

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company to Host Conference Call, November 13, 2024 at 4:30 p.m. ETSAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR ...

On Friday, Capricor Therapeutics Inc (CAPR) stock saw a decline, ending the day at $19.45 which represents a decrease of $-0.65 or -3.23% from the prior close of $20.1. The stock opened at $20.1 and ...

Capricor Therapeutics’ plan to seek early approval for a stem cell therapy for patients with Duchenne muscular dystrophy is ...

I’m a mom to seven children: Lexi, 23; Max, 18; Chance, 17; Rowen, 15; Charlie, 13; Mary, 10; and Callie, 2. As part of that job, I’m also a caregiver to Max ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. While barnstorming across ...

Deep-pocketed investors have adopted a bearish approach towards Capricor Therapeutics (NASDAQ:CAPR), and it's something market players shouldn't ignore. Our tracking of public options records at ...